Asset Details
Do you wish to reserve the book?
Molnupiravir: coding for catastrophe
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Molnupiravir: coding for catastrophe
Do you wish to request the book?
Molnupiravir: coding for catastrophe
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Molnupiravir: coding for catastrophe
2021
Overview
Molnupiravir, a wide-spectrum antiviral that is currently in phase 2/3 clinical trials for the treatment of COVID-19, is proposed to inhibit viral replication by a mechanism known as ‘lethal mutagenesis’. Two recently published studies reveal the biochemical and structural bases of how molnupiravir disrupts the fidelity of SARS-CoV-2 genome replication and prevents viral propagation by fostering error accumulation in a process referred to as ‘error catastrophe’.
Publisher
Nature Publishing Group US,Nature Publishing Group
Subject
/ Antiviral Agents - chemistry
/ Antiviral Agents - pharmacology
/ Antiviral Agents - therapeutic use
/ Biomedical and Life Sciences
/ Complications and side effects
/ COVID-19
/ Cytidine - analogs & derivatives
/ DNA-Directed RNA Polymerases - metabolism
/ Genome, Viral - drug effects
/ Genomes
/ Humans
/ Hydroxylamines - pharmacology
/ Hydroxylamines - therapeutic use
/ Severe acute respiratory syndrome coronavirus 2
/ Vaccines
